Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing mice

Abstract

Abstract. The present study was designed to investigate whether cyclooxygenase (COX) inhibitors (coxibs) could prolong survival time by attenuating the tumor growth of ovarian cancer xenograft-bearing mice. Tumor growth and survival time were observed and compared in mice which were treated with a COX-1 inhibitor (SC-560) and a COX-2 inhibitor (celecoxib) every other day for a 21 day period from the day of tumor formation. The trial lasted a total of 121 days. The combination therapy resulted in statistically significant inhibition of tumor size compared with the control group (P<0.05). Additionally, single treatment of SC-560 or celecoxib significantly prolonged the mean survival time of mice compared with the control group (P<0.05). We suggest that COX-1 and COX-2 inhibitors may improve survival and inhibit tumor growth, and that the tumor growth inhibition by coxibs may be the contributing factor for the prolonged survival time in mouse xenograft models.

The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer

“…In addition, celecoxib inhibited ovarian tumor growth, induced apoptosis and reduced angiogenesis in obese and non-obese KpB mice. Our results are in agreement with those previously reported in ovarian cancer cell lines and xenograft models [27, 33, 34], suggesting that celecoxib may have promise as a potential treatment for ovarian cancer.…”

“…Although celecoxib has been shown to inhibit tumor growth in several animal cancer models, including ovarian cancer xenograft-bearing mice [27, 34], less is known of celecoxib's impact on ovarian tumor growth in genetically engineered mouse models or in obese versus non-obese mice. In this study, we mimicked a clinically obese state of ovarian cancer by using the KpB ovarian cancer model and by feeding these mice either a LFD or HFD once the mice reached 3 weeks of age.…”

Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancer

“…Other non-opiate therapies that have been shown to reduce CIBP and disease progression in preclinical models of bone cancer are NSAIDS and inhibitors of COX-2 3,11,21,22,45,48 . Both these therapies have also been shown to slow the growth of a wide variety of cancers and are commonly used as a first line therapy to treat CIBP 3,11,21,22,45,48 .…”

“…Both these therapies have also been shown to slow the growth of a wide variety of cancers and are commonly used as a first line therapy to treat CIBP 3,11,21,22,45,48 . Additionally, at least in preclinical models, anti-NGF therapy has also been shown to reduce the growth of head and neck cancer as well as reducing tumor-induced bone remodeling and time to fracture in a mouse model of bone cancer pain 30,52,79,97 .…”

Alternative methanogenesis - Methanogenic potential of organosulfur administration

“…An important novel aspect of this process is CH 4 bioactivity [6]. While CH 4 is conventionally believed to be physiologically inert, anti-inflammatory effects were described for exogenous CH 4 in several experimental hypoxia-reoxygenation conditions [8]. Therefore, these and other data collectively raised the possibility that non-bacterial CH 4 emissions can be part of an adaptive response to oxido-reductive stress in eukaryotes [6,7].…”